Stability and in vitro metabolism of dipeptide model prodrugs with affinity for the oligopeptide transporter.
One approach to increase drug stability and to facilitate oral absorption of low bioavailability drugs may be to design oligopeptide ester prodrugs which are stable in the gastrointestinal tract, are transported via the oligopeptide transporter, and finally release the parent drug molecule into the blood circulation and/or by its site of action. In these kinds of prodrugs the ester linkage may be broken by pH dependent and/or enzyme catalyzed hydrolysis. The objective of the present study was to investigate the degradation mechanism and rate of the model compounds Glu(OBzl)-Sar, D-Glu(OBzl)-Ala and Asp(OBzl)-Sar in aqueous solution and in relevant biological media and to compare these results with those of our previous study of D-Asp(OBzl)-Ala. Furthermore, the resulting aqueous stability and in vitro metabolism data are related to our previous affinity data to evaluate if Glu-Sar, D-Glu-Ala, and Asp-Sar have potential as pro-moieties in these kinds of prodrugs. The degradation rates follow first-order kinetics, show maximun stability at pH 4-5 with maximum half-lives for Asp(OBzl)-Sar, Glu(OBzl)-Sar, and D-Glu(OBzl)-Ala of 115 h, 30 days and 152 days, respectively. The stability was dependent on buffer concentration, temperature, pH, and ionic strength. In biological media such as 80% human plasma, human gastric juice and intestinal fluid, and 10% rat jejunal homogenate at 37 degrees C, the half-lives were greater than 1 h except for the hydrolysis of Glu(OBzl)-Sar in 10% rat jejunal homogenate, where the half-life was approximately 16 min. All the stabilized dipeptides may have potential as drug carriers targeting hPepT1.
Lepist
E I
EI
The Royal Danish School of Pharmacy, Copenhagen, Denmark.
Kusk
T
T
Larsen
D H
DH
Andersen
D
D
Frokjaer
S
S
Taub
M E
ME
Veski
P
P
Lennernäs
H
H
Friedrichsen
G
G
Steffansen
B
B
D000818:Animals; D002021:Buffers; D015820:Cadherins; D002352:Carrier Proteins / Q000378:metabolism*; D004151:Dipeptides / Q000493:pharmacokinetics*; D004337:Drug Carriers; D005750:Gastric Juice / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D026901:Membrane Transport Proteins; D011355:Prodrugs / Q000493:pharmacokinetics*; D051381:Rats
C119646:(O-benzyl)aspartylalanine; D002021:Buffers; C490584:CDH17 protein, human; D015820:Cadherins; D002352:Carrier Proteins; C490586:Cdh17 protein, rat; D004151:Dipeptides; D004337:Drug Carriers; D026901:Membrane Transport Proteins; D011355:Prodrugs; C067802:intestinal peptide-proton cotransporter